Health New England to replace Humira coverage with lower-cost biosimilars

Health New England to replace Humira coverage with lower-cost biosimilars

SPRINGFIELD, Mass. (WWLP) - Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising he…

Health New England Shifts Coverage from Humira to Lower-cost Biosimilars

SPRINGFIELD — As part of its continued commitment to making healthcare more affordable and accessible, Health New England is shifting its coverage of Humira — a biologic medication used to treat inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and plaque psoriasis — to FDA-approved biosimilar medications for members of its commercial health plans. Biologic medications are made from natural and living organisms. Biosimilars …

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.